NxThera pioneered Convective Water Vapor Energy platform technology to treat a variety of endourological conditions. NxThera’s FDA-cleared Rezūm System is indicated to treat symptoms of BPH using thermal energy. The company is conducting advanced development and clinical research to potentially expand the application of its technology.
Boston Scientific today announced that it has entered into a definitive agreement to acquire NxThera, a privately-held company based in Maple Grove, Minnesota. NxThera developed and commercialized, in the United States and Europe, the Rezūm® system which is a minimally invasive therapy in a growing category of treatment options for men with symptoms arising from benign prostatic hyperplasia (BPH). The transaction consists of an upfront cash payment of $306 million, and up to an additional $100 million in potential commercial milestone payments over the next four years.
